Emer­gent clos­es on buy­ing small­pox drug Tem­bexa from Chimerix with a $238M pay­ment

It was on­ly last year that the oral treat­ment Tem­bexa was ap­proved by the FDA to treat small­pox, but the drug has al­ready changed hands.

Emer­gent BioSo­lu­tions, one of the pri­ma­ry drug man­u­fac­tur­ers for the US gov­ern­ment, has grabbed the glob­al rights for Tem­bexa from the North Car­oli­na-based biotech Chimerix. And that’s not the on­ly thing that Emer­gent is pick­ing up.

The man­u­fac­tur­er will al­so get Chimerix’s 10-year BAR­DA con­tract to pro­duce 1.7 mil­lion dos­es of the drug. The val­ue of the con­tract sits at $680 mil­lion as well as a “prod­uct pro­cure­ment” val­ued at $115 mil­lion. Ad­di­tion­al op­tions are val­ued at $551 mil­lion, which can be com­mit­ted at BAR­DA’s dis­cre­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.